Mondher MD - Innate Pharma Chairman CEO
| IPH Stock | EUR 1.43 0.10 6.54% |
Insider
Mondher MD is Chairman CEO of Innate Pharma
| Age | 65 |
| Phone | 33 4 30 30 30 30 |
| Web | https://www.innate-pharma.com |
Innate Pharma Management Efficiency
The company has return on total asset (ROA) of (0.043) % which means that it has lost $0.043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1731) %, meaning that it generated substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yvoine Remy | Eurofins Scientific SE | N/A | |
| Joachim Reichelt | Eurofins Scientific SE | N/A | |
| John Mackay | Sartorius Stedim Biotech | 61 | |
| Gabriel Julia | Eurofins Scientific SE | N/A | |
| Stanislas Gramont | SEB SA | 57 | |
| Joachim Kreuzburg | Sartorius Stedim Biotech | 58 | |
| Martin Zouhar | SEB SA | N/A | |
| Pierre Boulud | Biomerieux SA | 52 | |
| Mark Miller | Biomerieux SA | N/A | |
| Olivier Guitard | Sartorius Stedim Biotech | N/A | |
| Isabelle Posth | SEB SA | N/A | |
| Alexandre Merieux | Biomerieux SA | 49 | |
| Franois Lacoste | Biomerieux SA | N/A | |
| Laurent Lebras | Eurofins Scientific SE | N/A | |
| Cyril Buxtorf | SEB SA | 57 | |
| Benedikt Orzelek | Sartorius Stedim Biotech | N/A | |
| Guillaume Bouhours | Biomerieux SA | 47 | |
| Rajesh Saigal | Eurofins Scientific SE | N/A | |
| Petra Kirchhoff | Sartorius Stedim Biotech | 54 | |
| Sandra Hoeylaerts | Eurofins Scientific SE | N/A | |
| Timothy Oostdyk | Eurofins Scientific SE | N/A | |
Management Performance
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 |
Innate Pharma Leadership Team
Elected by the shareholders, the Innate Pharma's board of directors comprises two types of representatives: Innate Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innate. The board's role is to monitor Innate Pharma's management team and ensure that shareholders' interests are well served. Innate Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innate Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DVM MBA, VP Founder | ||
| Frederic MBA, VP CFO | ||
| Odile Belzunce, VP Operations | ||
| Mondher MD, Chairman CEO | ||
| Herve Brailly, Chairman of the Management Board, Member of the Executive Committee, CEO | ||
| Alessandro MD, Founder | ||
| Jean Fourni, Founder | ||
| Marc Bonneville, Founder | ||
| Yannis Morel, Member of the Executive Committee, Executive Vice President Business Development | ||
| Franois Romagn, Founder |
Innate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innate Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 86.87 M | |||
| Shares Outstanding | 80.2 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 125.20 X | |||
| Price To Book | 1.43 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.